title: Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: Retrospective study.
abstract: Although conventional glucocorticosteroids are the main treatments for active Crohn's disease, several problems are associated with steroid dependence and steroid-related adverse events. To assess the efficacy and safety of oral beclomethasone dipropionate (BDP) coated tablets in adults with mild-to-moderate Crohn's disease. Thirty-four patients (age 18-70years) with a diagnosis of Crohn's disease confirmed by conventional criteria (barium enema, clinical criteria, colonoscopy, histology) were retrospectively evaluated in the study. All subjects received a treatment schedule with BDP 5-10mg/day for 24weeks. BDP significantly (p=0.005) reduced mean Crohn's Disease Activity Index (CDAI) score from 169.6 at baseline to 123.2 after 24weeks. Clinical success was evident at 24weeks in 66.7% of patients with initial active disease, and remission was maintained at week 24 in 93.8% of patients with remission at baseline. Overall, female non-smokers had the best response to treatment. BDP was well tolerated and the only adverse events observed were nausea (n=1), facial erythema (n=1) and one patient with raised fasting blood glucose level. These results clearly suggest that oral BDP coated tablets are effective and safe for treatment of mild-to-moderate Crohn's disease of ileal or ileal-right colonic localisation.
authors.affiliation: SC Gastro-Epatologia DU, Ospedale S. Giovanni Battista, Molinette C.so Bramante 88, Torino, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Astegiano
authors.forename: N
authors.initials: N
authors.lastname: Pagano
authors.forename: N
authors.initials: N
authors.lastname: Sapone
authors.forename: D
authors.initials: D
authors.lastname: Simondi
authors.forename: L
authors.initials: L
authors.lastname: Bertolusso
authors.forename: F
authors.initials: F
authors.lastname: Bresso
authors.forename: B
authors.initials: B
authors.lastname: Demarchi
authors.forename: R
authors.initials: R
authors.lastname: Pellicano
authors.forename: R
authors.initials: R
authors.lastname: Bonardi
authors.forename: S
authors.initials: S
authors.lastname: Marconi
authors.forename: M
authors.initials: M
authors.lastname: Rizzetto
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001507:Beclomethasone / Q000008:administration & dosage* / Q000633:toxicity; D003106:Colon; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D004341:Drug Evaluation; D004890:Erythema / Q000139:chemically induced; D005260:Female; D006801:Humans; D007077:Ileal Diseases / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D012074:Remission Induction; D012189:Retrospective Studies; D012737:Sex Factors
chemical_list: D001507:Beclomethasone